Bill Text: IL HB3680 | 2017-2018 | 100th General Assembly | Introduced


Bill Title: Amends the Illinois Controlled Substances Act. Adds 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (some trade or other name: pink; U-47700) as a Schedule I controlled substance.

Spectrum: Partisan Bill (Democrat 6-0)

Status: (Failed) 2019-01-08 - Session Sine Die [HB3680 Detail]

Download: Illinois-2017-HB3680-Introduced.html


100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018
HB3680

Introduced , by Rep. Brandon W. Phelps

SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204

Amends the Illinois Controlled Substances Act. Adds 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (some trade or other name: pink; U-47700) as a Schedule I controlled substance.
LRB100 10855 RLC 21089 b

A BILL FOR

HB3680LRB100 10855 RLC 21089 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 204 as follows:
6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
7 Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9 (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including their
11isomers, esters, ethers, salts, and salts of isomers, esters,
12and ethers, whenever the existence of such isomers, esters,
13ethers and salts is possible within the specific chemical
14designation:
15 (1) Acetylmethadol;
16 (1.1) Acetyl-alpha-methylfentanyl
17 (N-[1-(1-methyl-2-phenethyl)-
18 4-piperidinyl]-N-phenylacetamide);
19 (2) Allylprodine;
20 (3) Alphacetylmethadol, except
21 levo-alphacetylmethadol (also known as levo-alpha-
22 acetylmethadol, levomethadyl acetate, or LAAM);
23 (4) Alphameprodine;

HB3680- 2 -LRB100 10855 RLC 21089 b
1 (5) Alphamethadol;
2 (6) Alpha-methylfentanyl
3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
5 propanilido) piperidine;
6 (6.1) Alpha-methylthiofentanyl
7 (N-[1-methyl-2-(2-thienyl)ethyl-
8 4-piperidinyl]-N-phenylpropanamide);
9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10 (7.1) PEPAP
11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12 (8) Benzethidine;
13 (9) Betacetylmethadol;
14 (9.1) Beta-hydroxyfentanyl
15 (N-[1-(2-hydroxy-2-phenethyl)-
16 4-piperidinyl]-N-phenylpropanamide);
17 (10) Betameprodine;
18 (11) Betamethadol;
19 (12) Betaprodine;
20 (13) Clonitazene;
21 (14) Dextromoramide;
22 (15) Diampromide;
23 (16) Diethylthiambutene;
24 (17) Difenoxin;
25 (18) Dimenoxadol;
26 (19) Dimepheptanol;

HB3680- 3 -LRB100 10855 RLC 21089 b
1 (20) Dimethylthiambutene;
2 (21) Dioxaphetylbutyrate;
3 (22) Dipipanone;
4 (23) Ethylmethylthiambutene;
5 (24) Etonitazene;
6 (25) Etoxeridine;
7 (26) Furethidine;
8 (27) Hydroxpethidine;
9 (28) Ketobemidone;
10 (29) Levomoramide;
11 (30) Levophenacylmorphan;
12 (31) 3-Methylfentanyl
13 (N-[3-methyl-1-(2-phenylethyl)-
14 4-piperidyl]-N-phenylpropanamide);
15 (31.1) 3-Methylthiofentanyl
16 (N-[(3-methyl-1-(2-thienyl)ethyl-
17 4-piperidinyl]-N-phenylpropanamide);
18 (32) Morpheridine;
19 (33) Noracymethadol;
20 (34) Norlevorphanol;
21 (35) Normethadone;
22 (36) Norpipanone;
23 (36.1) Para-fluorofentanyl
24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25 4-piperidinyl]propanamide);
26 (37) Phenadoxone;

HB3680- 4 -LRB100 10855 RLC 21089 b
1 (38) Phenampromide;
2 (39) Phenomorphan;
3 (40) Phenoperidine;
4 (41) Piritramide;
5 (42) Proheptazine;
6 (43) Properidine;
7 (44) Propiram;
8 (45) Racemoramide;
9 (45.1) Thiofentanyl
10 (N-phenyl-N-[1-(2-thienyl)ethyl-
11 4-piperidinyl]-propanamide);
12 (46) Tilidine;
13 (47) Trimeperidine;
14 (48) Beta-hydroxy-3-methylfentanyl (other name:
15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16 N-phenylpropanamide).
17 (c) Unless specifically excepted or unless listed in
18another schedule, any of the following opium derivatives, its
19salts, isomers and salts of isomers, whenever the existence of
20such salts, isomers and salts of isomers is possible within the
21specific chemical designation:
22 (1) Acetorphine;
23 (2) Acetyldihydrocodeine;
24 (3) Benzylmorphine;
25 (4) Codeine methylbromide;
26 (5) Codeine-N-Oxide;

HB3680- 5 -LRB100 10855 RLC 21089 b
1 (6) Cyprenorphine;
2 (7) Desomorphine;
3 (8) Diacetyldihydromorphine (Dihydroheroin);
4 (9) Dihydromorphine;
5 (10) Drotebanol;
6 (11) Etorphine (except hydrochloride salt);
7 (12) Heroin;
8 (13) Hydromorphinol;
9 (14) Methyldesorphine;
10 (15) Methyldihydromorphine;
11 (16) Morphine methylbromide;
12 (17) Morphine methylsulfonate;
13 (18) Morphine-N-Oxide;
14 (19) Myrophine;
15 (20) Nicocodeine;
16 (21) Nicomorphine;
17 (22) Normorphine;
18 (23) Pholcodine;
19 (24) Thebacon.
20 (d) Unless specifically excepted or unless listed in
21another schedule, any material, compound, mixture, or
22preparation which contains any quantity of the following
23hallucinogenic substances, or which contains any of its salts,
24isomers and salts of isomers, whenever the existence of such
25salts, isomers, and salts of isomers is possible within the
26specific chemical designation (for the purposes of this

HB3680- 6 -LRB100 10855 RLC 21089 b
1paragraph only, the term "isomer" includes the optical,
2position and geometric isomers):
3 (1) 3,4-methylenedioxyamphetamine
4 (alpha-methyl,3,4-methylenedioxyphenethylamine,
5 methylenedioxyamphetamine, MDA);
6 (1.1) Alpha-ethyltryptamine
7 (some trade or other names: etryptamine;
8 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
9 3-(2-aminobutyl)indole; a-ET; and AET);
10 (2) 3,4-methylenedioxymethamphetamine (MDMA);
11 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
12 (also known as: N-ethyl-alpha-methyl-
13 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
14 and MDEA);
15 (2.2) N-Benzylpiperazine (BZP);
16 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
17 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
18 (4) 3,4,5-trimethoxyamphetamine (TMA);
19 (5) (Blank);
20 (6) Diethyltryptamine (DET);
21 (7) Dimethyltryptamine (DMT);
22 (7.1) 5-Methoxy-diallyltryptamine;
23 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
24 (9) Ibogaine (some trade and other names:
25 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
26 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

HB3680- 7 -LRB100 10855 RLC 21089 b
1 indole; Tabernanthe iboga);
2 (10) Lysergic acid diethylamide;
3 (10.1) Salvinorin A;
4 (10.5) Salvia divinorum (meaning all parts of the plant
5 presently classified botanically as Salvia divinorum,
6 whether growing or not, the seeds thereof, any extract from
7 any part of that plant, and every compound, manufacture,
8 salts, isomers, and salts of isomers whenever the existence
9 of such salts, isomers, and salts of isomers is possible
10 within the specific chemical designation, derivative,
11 mixture, or preparation of that plant, its seeds or
12 extracts);
13 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
14 (12) Peyote (meaning all parts of the plant presently
15 classified botanically as Lophophora williamsii Lemaire,
16 whether growing or not, the seeds thereof, any extract from
17 any part of that plant, and every compound, manufacture,
18 salts, derivative, mixture, or preparation of that plant,
19 its seeds or extracts);
20 (13) N-ethyl-3-piperidyl benzilate (JB 318);
21 (14) N-methyl-3-piperidyl benzilate;
22 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
23 (also known as N-hydroxy-alpha-methyl-
24 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
25 (15) Parahexyl; some trade or other names:
26 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

HB3680- 8 -LRB100 10855 RLC 21089 b
1 dibenzo (b,d) pyran; Synhexyl;
2 (16) Psilocybin;
3 (17) Psilocyn;
4 (18) Alpha-methyltryptamine (AMT);
5 (19) 2,5-dimethoxyamphetamine
6 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
7 (20) 4-bromo-2,5-dimethoxyamphetamine
8 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
9 4-bromo-2,5-DMA);
10 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
11 Some trade or other names: 2-(4-bromo-
12 2,5-dimethoxyphenyl)-1-aminoethane;
13 alpha-desmethyl DOB, 2CB, Nexus;
14 (21) 4-methoxyamphetamine
15 (4-methoxy-alpha-methylphenethylamine;
16 paramethoxyamphetamine; PMA);
17 (22) (Blank);
18 (23) Ethylamine analog of phencyclidine.
19 Some trade or other names:
20 N-ethyl-1-phenylcyclohexylamine,
21 (1-phenylcyclohexyl) ethylamine,
22 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
23 (24) Pyrrolidine analog of phencyclidine. Some trade
24 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
25 PHP;
26 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

HB3680- 9 -LRB100 10855 RLC 21089 b
1 (26) 2,5-dimethoxy-4-ethylamphetamine
2 (another name: DOET);
3 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
4 (another name: TCPy);
5 (28) (Blank);
6 (29) Thiophene analog of phencyclidine (some trade
7 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
8 2-thienyl analog of phencyclidine; TPCP; TCP);
9 (30) Bufotenine (some trade or other names:
10 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
11 3-(2-dimethylaminoethyl)-5-indolol;
12 5-hydroxy-N,N-dimethyltryptamine;
13 N,N-dimethylserotonin; mappine);
14 (31) 1-Pentyl-3-(1-naphthoyl)indole
15 Some trade or other names: JWH-018;
16 (32) 1-Butyl-3-(1-naphthoyl)indole
17 Some trade or other names: JWH-073;
18 (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]-
19 (2-iodophenyl)methanone
20 Some trade or other names: AM-694;
21 (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
22 (2-methyloctan-2-yl)phenol
23 Some trade or other names: CP 47,497
24 and its C6, C8 and C9 homologs;
25 (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
26 (2-methyloctan-2-yl)phenol), where side chain n=5;

HB3680- 10 -LRB100 10855 RLC 21089 b
1 and homologues where side chain n=4, 6, or 7; Some
2 trade or other names: CP 47,497;
3 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
4 (2-methyloctan-2-yl)-6a,7,
5 10,10a-tetrahydrobenzo[c]chromen-1-ol
6 Some trade or other names: HU-210;
7 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
8 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
9 tetrahydrobenzo[c]chromen-1-ol, its isomers,
10 salts, and salts of isomers; Some trade or other
11 names: HU-210, Dexanabinol;
12 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
13 6,6-dimethyl-3-(2-methyloctan-2-yl)-
14 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
15 Some trade or other names: HU-211;
16 (37) (2-methyl-1-propyl-1H-indol-
17 3-yl)-1-naphthalenyl-methanone
18 Some trade or other names: JWH-015;
19 (38) 4-methoxynaphthalen-1-yl-
20 (1-pentylindol-3-yl)methanone
21 Some trade or other names: JWH-081;
22 (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
23 Some trade or other names: JWH-122;
24 (40) 2-(2-methylphenyl)-1-(1-pentyl-
25 1H-indol-3-yl)-ethanone
26 Some trade or other names: JWH-251;

HB3680- 11 -LRB100 10855 RLC 21089 b
1 (41) 1-(2-cyclohexylethyl)-3-
2 (2-methoxyphenylacetyl)indole
3 Some trade or other names: RCS-8, BTW-8 and SR-18;
4 (42) Any compound structurally derived from
5 3-(1-naphthoyl)indole or 1H-indol-3-yl-
6 (1-naphthyl)methane by substitution at the
7 nitrogen atom of the indole ring by alkyl, haloalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
10 or 2-(4-morpholinyl)ethyl whether or not further
11 substituted in the indole ring to any extent, whether
12 or not substituted in the naphthyl ring to any extent.
13 Examples of this structural class include, but are
14 not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
15 and JWH-185;
16 (43) Any compound structurally derived from
17 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
18 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
20 aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
21 or 2-(4-morpholinyl)ethyl, whether or not further
22 substituted in the pyrrole ring to any extent, whether
23 or not substituted in the naphthyl ring to any extent.
24 Examples of this structural class include, but are not
25 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
26 JWH-368;

HB3680- 12 -LRB100 10855 RLC 21089 b
1 (44) Any compound structurally derived from
2 1-(1-naphthylmethyl)indene by substitution
3 at the 3-position of the indene ring by alkyl, haloalkyl,
4 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
5 halide, alkyl aryl halide, 1-(N-methyl-
6 2-piperidinyl)methyl, or 2-(4-
7 morpholinyl)ethyl whether or not further substituted in
8 the indene ring to any extent, whether or not substituted
9 in the naphthyl ring to any extent. Examples of
10 this structural class include, but are not
11 limited to, JWH-176;
12 (45) Any compound structurally derived from
13 3-phenylacetylindole by substitution at the
14 nitrogen atom of the indole ring with alkyl, haloalkyl,
15 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
16 halide, alkyl aryl halide, 1-(N-methyl-2-
17 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
18 whether or not further substituted in the indole ring
19 to any extent, whether or not substituted in the phenyl
20 ring to any extent. Examples of this structural
21 class include, but are not limited to, JWH-167,
22 JWH-250, JWH-251, and RCS-8;
23 (46) Any compound structurally derived from
24 2-(3-hydroxycyclohexyl)phenol by substitution
25 at the 5-position of the phenolic ring by alkyl,
26 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

HB3680- 13 -LRB100 10855 RLC 21089 b
1 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
2 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
3 whether or not substituted in the cyclohexyl ring to any
4 extent. Examples of this structural class
5 include, but are not limited to, CP 47,
6 497 and its C8 homologue (cannabicyclohexanol);
7 (46.1) Benzoylindoles: Any compound
8 containing a 3-(benzoyl) indole structure with
9 substitution at the nitrogen atom of the
10 indole ring by an alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl,
12 1-(N-methyl-2-piperidinyl)methyl,
13 or 2-(4-morpholinyl)ethyl group
14 whether or not further substituted
15 in the indole ring to any extent and
16 whether or not substituted in the phenyl ring
17 to any extent. Examples of this structural class
18 include, but are not limited, to, AM-630,
19 AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;
20 (47) 3,4-Methylenedioxymethcathinone
21 Some trade or other names: Methylone;
22 (48) 3,4-Methyenedioxypyrovalerone
23 Some trade or other names: MDPV;
24 (49) 4-Methylmethcathinone
25 Some trade or other names: Mephedrone;
26 (50) 4-methoxymethcathinone;

HB3680- 14 -LRB100 10855 RLC 21089 b
1 (51) 4-Fluoromethcathinone;
2 (52) 3-Fluoromethcathinone;
3 (53) 2,5-Dimethoxy-4-(n)-propylthio-
4 phenethylamine;
5 (54) 5-Methoxy-N,N-diisopropyltryptamine;
6 (55) Pentedrone;
7 (56) 4-iodo-2,5-dimethoxy-N-((2-methoxy
8 phenyl)methyl)-benzeneethanamine
9 (trade or other name: 25I-NBOMe);
10 (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)
11 methyl]-benzeneethanamine (trade or other name:
12 25C-NBOMe);
13 (58) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)
14 methyl]-benzeneethanamine (trade or other name:
15 25B-NBOMe);
16 (59) 3-cyclopropoylindole with
17 substitution at the nitrogen atom of the
18 indole ring by alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl
20 halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not
23 further substituted on the indole ring
24 to any extent, whether or not substituted
25 on the cyclopropyl ring to any extent:
26 including, but not limited to, XLR11,

HB3680- 15 -LRB100 10855 RLC 21089 b
1 UR144, FUB-144;
2 (60) 3-adamantoylindole with
3 substitution at the nitrogen atom of the
4 indole ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl,
6 aryl halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not
9 further substituted on the indole ring to
10 any extent, whether or not substituted on
11 the adamantyl ring to any extent: including,
12 but not limited to, AB-001;
13 (61) N-(adamantyl)-indole-3-carboxamide
14 with substitution at the nitrogen atom of the
15 indole ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide,
17 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
18 or 2-(4-morpholinyl)ethyl, whether or not further
19 substituted on the indole ring to any extent, whether
20 or not substituted on the adamantyl ring to any
21 extent: including, but not limited to,
22 APICA/2NE-1, STS-135;
23 (62) N-(adamantyl)-indazole-3-carboxamide
24 with substitution at a nitrogen atom of the indazole
25 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
26 cycloalkylethyl, aryl halide, alkyl aryl halide,

HB3680- 16 -LRB100 10855 RLC 21089 b
1 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further
3 substituted on the indazole ring to any extent,
4 whether or not substituted on the adamantyl
5 ring to any extent: including, but not limited
6 to, AKB48, 5F-AKB48;
7 (63) 1H-indole-3-carboxylic acid 8-quinolinyl
8 ester with substitution at the nitrogen atom of the
9 indole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
11 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further
13 substituted on the indole ring to any extent,
14 whether or not substituted on the quinoline ring
15 to any extent: including, but not limited to, PB22,
16 5F-PB22, FUB-PB-22;
17 (64) 3-(1-naphthoyl)indazole with
18 substitution at the nitrogen atom of the
19 indazole ring by alkyl, haloalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl,
21 aryl halide, alkyl aryl halide,
22 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further
24 substituted on the indazole ring to any extent,
25 whether or not substituted on the naphthyl ring
26 to any extent: including, but not limited to,

HB3680- 17 -LRB100 10855 RLC 21089 b
1 THJ-018, THJ-2201;
2 (65) 2-(1-naphthoyl)benzimidazole with
3 substitution at the nitrogen atom of the benzimidazole
4 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5 cycloalkylethyl, aryl halide, alkyl aryl halide,
6 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further
8 substituted on the benzimidazole ring to any extent,
9 whether or not substituted on the naphthyl ring to
10 any extent: including, but not limited to, FUBIMINA;
11 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)
12 -1H-indazole-3-carboxamide with substitution on the
13 nitrogen atom of the indazole ring by alkyl,
14 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
16 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
17 whether or not further substituted on the indazole
18 ring to any extent: including, but not limited to,
19 AB-PINACA, AB-FUBINACA, AB-CHMINACA;
20 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-
21 2-yl)-1H-indazole-3-carboxamide with substitution
22 on the nitrogen atom of the indazole ring by alkyl,
23 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
24 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
25 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether
26 or not further substituted on the indazole ring to any

HB3680- 18 -LRB100 10855 RLC 21089 b
1 extent: including, but not limited to,
2 ADB-PINACA, ADB-FUBINACA;
3 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
4 1H-indole-3-carboxamide with substitution on the nitrogen
5 atom of the indole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
7 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further
9 substituted on the indole ring to any extent:
10 including, but not limited to, ADBICA, 5F-ADBICA;
11 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-
12 1H-indole-3-carboxamide with substitution on the
13 nitrogen atom of the indole ring by alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
15 halide, alkyl aryl halide, 1-(N-methyl-2-
16 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
17 whether or not further substituted on the indole
18 ring to any extent: including, but not limited
19 to, ABICA, 5F-ABICA;
20 (70) Methyl 2-(1H-indazole-3-carboxamido)-
21 3-methylbutanoate with substitution on the nitrogen
22 atom of the indazole ring by alkyl, haloalkyl,
23 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
24 halide, alkyl aryl halide, 1-(N-methyl-2-
25 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
26 whether or not further substituted on the indazole

HB3680- 19 -LRB100 10855 RLC 21089 b
1 ring to any extent: including, but not
2 limited to, AMB, 5F-AMB; .
3 (71) 3,4-Dichloro-N-[2-(dimethylamino)
4 cyclohexyl]-N-methylbenzamide (Some trade or other
5 name: pink; U-47700).
6 (e) Unless specifically excepted or unless listed in
7another schedule, any material, compound, mixture, or
8preparation which contains any quantity of the following
9substances having a depressant effect on the central nervous
10system, including its salts, isomers, and salts of isomers
11whenever the existence of such salts, isomers, and salts of
12isomers is possible within the specific chemical designation:
13 (1) mecloqualone;
14 (2) methaqualone; and
15 (3) gamma hydroxybutyric acid.
16 (f) Unless specifically excepted or unless listed in
17another schedule, any material, compound, mixture, or
18preparation which contains any quantity of the following
19substances having a stimulant effect on the central nervous
20system, including its salts, isomers, and salts of isomers:
21 (1) Fenethylline;
22 (2) N-ethylamphetamine;
23 (3) Aminorex (some other names:
24 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
25 4-5-dihydro-5-phenyl-2-oxazolamine) and its
26 salts, optical isomers, and salts of optical isomers;

HB3680- 20 -LRB100 10855 RLC 21089 b
1 (4) Methcathinone (some other names:
2 2-methylamino-1-phenylpropan-1-one;
3 Ephedrone; 2-(methylamino)-propiophenone;
4 alpha-(methylamino)propiophenone; N-methylcathinone;
5 methycathinone; Monomethylpropion; UR 1431) and its
6 salts, optical isomers, and salts of optical isomers;
7 (5) Cathinone (some trade or other names:
8 2-aminopropiophenone; alpha-aminopropiophenone;
9 2-amino-1-phenyl-propanone; norephedrone);
10 (6) N,N-dimethylamphetamine (also known as:
11 N,N-alpha-trimethyl-benzeneethanamine;
12 N,N-alpha-trimethylphenethylamine);
13 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
14 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
15 (8) 3,4-Methylenedioxypyrovalerone (MDPV).
16 (g) Temporary listing of substances subject to emergency
17scheduling. Any material, compound, mixture, or preparation
18that contains any quantity of the following substances:
19 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
20 (benzylfentanyl), its optical isomers, isomers, salts,
21 and salts of isomers;
22 (2) N-[1(2-thienyl)
23 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
24 its optical isomers, salts, and salts of isomers.
25 (h) Synthetic cathinones. Unless specifically excepted,
26any chemical compound not including bupropion, structurally

HB3680- 21 -LRB100 10855 RLC 21089 b
1derived from 2-aminopropan-1-one by substitution at the
21-position with either phenyl, naphthyl, or thiophene ring
3systems, whether or not the compound is further modified in one
4or more of the following ways:
5 (1) by substitution in the ring system to
6 any extent with alkyl, alkylenedioxy, alkoxy,
7 haloalkyl, hydroxyl, or halide substituents, whether
8 or not further substituted in the ring system
9 by one or more other univalent substituents.
10 Examples of this class include, but are not
11 limited to, 3,4-Methylenedioxycathinone
12 (bk-MDA);
13 (2) by substitution at the 3-position
14 with an acyclic alkyl substituent. Examples of
15 this class include, but are not limited to,
16 2-methylamino-1-phenylbutan-1-one
17 (buphedrone); or
18 (3) by substitution at the 2-amino nitrogen
19 atom with alkyl, dialkyl, benzyl, or methoxybenzyl
20 groups, or by inclusion of the 2-amino nitrogen atom
21 in a cyclic structure. Examples of this class include,
22 but are not limited to, Dimethylcathinone, Ethcathinone,
23 and a-Pyrrolidinopropiophenone (a-PPP).
24(Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
2510-25-16.)
feedback